Merck & Co Inc (N:MRK)

Sector:  Healthcare Industry:  Pharmaceuticals
See Regulatory Filings on SEC
Company Contact
Address: 2000 Galloping Hill Road
Tel: N/A
IR: See website
Key People
Robert M. Davis
Chairman of the Board, President, Chief Executive Officer
Chirfi Guindo
Senior Vice President, Chief Marketing Officer - Human Health
Steven C. Mizell
Executive Vice President, Chief Human Resources Officer
David M. Williams
Executive Vice President, Chief Information and Digital Officer
Jennifer L. Zachary
Executive Vice President, General Counsel, Corporate Secretary
Sanat Chattopadhyay
Executive Vice President and President - Merck Manufacturing Division
Richard R. Deluca
Executive Vice President, President - Merck Animal Health
Cristal N. Downing
Executive Vice President, Chief Communications and Public Affairs Officer
Dean Y. Li
Executive Vice President, President - Merck Research Laboratories
Rita A. Karachun
Senior Vice President Finance - Global Controller
Business Overview
Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription for the treatment of human disorders. It sells human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Company's Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products as well as health management solutions for the prevention, treatment and control of disease in all livestock and companion animal species. The Company's product MK-7240 is used for the treatment of immune-mediated diseases including ulcerative colitis, and Crohn's disease.
Financial Overview
For the six months ended 30 June 2023, Merck & Co Inc revenues decreased 3% to $29.52B. Net loss totaled $3.15B vs. income of $8.25B. Revenues reflect Merck Pharmaceutical segment decrease of 2% to $29.13B, Other segment decrease of 42% to $396M, Europe, Middle East and Africa segment decrease of 16% to $6.65B, Japan segment decrease of 32% to $1.43B. Net loss reflects Research and Development increase from $5.35B to $13.32B (expense).
Employees: 69,000 as of Dec 31, 2022
Reporting Currency: U.S. Dollars
Enterprise value: $295,197M as of Jun 30, 2023
Annual revenue (TTM): $58,311M as of Jun 30, 2023
EBITDA (TTM): $15,796M as of Jun 30, 2023
Net annual income (TTM): $3,111M as of Jun 30, 2023
Free cash flow (TTM): $3,593M as of Jun 30, 2023
Net Debt Last Fiscal Year: $30,533M as of Jun 30, 2023
Shares outstanding: 2,537,521,169 as of Jul 31, 2023
Index Membership: S&P 500, Dow Industry
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.